Potent suppression of hydrophobic bile acids by aldafermin an FGF19 analogue across metabolic and cholestatic liver diseases

摘要

Higher serum bile acid levels are associated with an increased risk of cirrhosis and liver-related morbidity and mortality. Herein, we report secondary analyses of aldafermin, an engineered analogue of the gut hormone fibroblast growth factor 19, on the circulating bile acid profile in prospective, phase II studies in patients with metabolic or cholestatic liver disease.